CVS Health on Wednesday blew past second-quarter earnings and revenue estimates and raised its 2026 guidance, as its insurance unit Aetna shows signs of recovery. 

CVS, which operates the nation’s largest pharmacy chain, sees full-year adjusted profit coming in between $7.90 and $8.10 per share. That’s up from a previous guidance of $7.30 to $7.50 per share. 

The company also expects revenue of at least $414 billion in 2026, up from its prior outlook of at least $405 billion.

In a release, CVS said the higher profit guidance reflects increases in its insurance and retail pharmacy segment, but noted that the company is maintaining a “cautious view” for the rest of the year amid high medical costs and potential challenges in the broader economy.

Shares of the healthcare giant rose 1% in premarket trading Wednesday.  

All three of the healthcare giant’s business segments – insurance, pharmacy and health services —surpassed Wall Street’s revenue expectations. But Aetna’s results have been top of mind for investors, who have watched high medical costs in privately run Medicare plans batter several major health insurers for the last two years. 

The results indicated continued progress in CVS’ broader turnaround plan, which has involved cutting $2 billion in costs, closing underperforming stores, shuffling leadership and reducing costs within Medicare Advantage plans. CVS’ report also adds to a solid second quarter for the broader health insurance sector. 

Also on Wednesday, CVS announced a new collaboration with Eli Lilly that will make its obesity injection Zepbound and new weight loss pill Foundayo accessible to eligible patients on the CVS Health app. That offering, which will be available by early in the fourth quarter, will include both patients with insurance coverage and those paying out of pocket.

Here’s what CVS reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

• Earnings per share: $2.58 adjusted vs. $1.85 expected
• Revenue: $106.10 billion vs. $100.11 billion expected

The company posted net income of $2.98 billion, or $2.31 per share, for the second quarter. That compares with net income of $1.02 billion, or 80 cents per share, for the same period a year ago. 

Excluding certain items, such as restructuring charges and capital losses, adjusted earnings were $2.58 per share for the quarter.

CVS booked sales of $106.10 billion for the second quarter, up about 7% from the same period a year ago, as all three of its business segments showed growth.